Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Clinical trial NCT05158062 · UNKNOWN
Trial details
- NCT number
- NCT05158062
- Sponsor
- Kosei Hasegawa, MD, PhD
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-20
- Primary completion
- 2024-11-30
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.